Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp IGXT


Primary Symbol: T.IGX

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines

GlobeNewswire December 1, 2014

IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines

Newsfile December 1, 2014

IIROC Trading Resumption - IGX

Canada NewsWire November 26, 2014

IIROC Trade Resumption - IntelGenx Corp.

Newsfile November 26, 2014

IntelGenx Announces Update to Settlement of U.S. Patent Litigation Related to Forfivo XL(R)

Newsfile November 26, 2014

IIROC Trading Halt - IGX

Canada NewsWire November 25, 2014

IIROC Trade Halt - IntelGenx Corp.

Newsfile November 25, 2014

IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)

GlobeNewswire November 25, 2014

IntelGenx Announces Settlement of U.S. Patent Litigation Related to Forfivo XL(R)

Newsfile November 25, 2014

IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference

GlobeNewswire November 18, 2014

IntelGenx to Present at Singular Research's Best of the Uncovered 2014 NYC Fall Conference

Newsfile November 18, 2014

IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update

GlobeNewswire November 12, 2014

IntelGenx Reports Q3, 2014 Results and Provides Corporate Development Update

Newsfile November 12, 2014

IntelGenx Announces Successful Clinical Study for Schizophrenia

GlobeNewswire November 3, 2014

IntelGenx Announces Successful Clinical Study for Schizophrenia

Newsfile November 3, 2014

IntelGenx Founder Returns as President and CEO

GlobeNewswire October 2, 2014

IntelGenx Founder Returns as President and CEO

Newsfile October 2, 2014

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)

GlobeNewswire October 1, 2014

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)

Newsfile October 1, 2014

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R) (formerly RHB-103)

GlobeNewswire October 1, 2014